Key Events This Week
22 Jun: Stock opened at Rs.147.80, down 2.09% amid valuation upgrade
23 Jun: MarketsMOJO upgraded Makers Laboratories Ltd to Hold on improved valuation and financial trends
24 Jun: Stock rebounded with a 1.85% gain to Rs.145.90
25 Jun: Week closed at Rs.147.30, down 0.31% on the day
22 June 2026: Week Opens Lower Amid Valuation Upgrade
Makers Laboratories Ltd commenced the week at Rs.147.80, marking a 2.09% decline from the prior close of Rs.150.95. This drop coincided with the announcement of an upgrade by MarketsMOJO from 'Sell' to 'Hold' based on improved valuation and financial trends. The stock’s price-to-earnings ratio of 37.11 and an enterprise value to EBITDA ratio of 5.51 positioned it favourably against peers, signalling a more attractive valuation despite the initial price dip. The Sensex, in contrast, gained 0.46% to close at 36,342.26, indicating broader market strength that the stock did not immediately mirror.
23 June 2026: Upgrade Announcement Spurs Mixed Reaction
On 23 June, Makers Laboratories Ltd’s stock price fell further by 3.08% to Rs.143.25, even as MarketsMOJO publicly upgraded the company’s mojo grade to 'Hold'. The upgrade was driven by a shift in valuation grade from 'Fair' to 'Attractive', supported by competitive price multiples relative to sector peers such as Bliss GVS Pharma and NGL Fine Chem, which trade at higher valuations. The company’s recent quarterly performance showed its highest net sales of ₹35.75 crores and peak PBDIT of ₹5.27 crores, signalling operational momentum. However, the stock’s decline on the day reflected investor caution amid mixed financial signals and a Sensex drop of 1.05% to 35,959.97.
24 June 2026: Price Recovery on Moderate Volume
The stock rebounded on 24 June, gaining 1.85% to close at Rs.145.90. This recovery followed the prior day’s sell-off and coincided with a Sensex gain of 0.53% to 36,151.68. The volume on this day was notably lower at 2,961 shares, suggesting a cautious but positive investor response to the valuation upgrade and recent financial disclosures. The company’s price-to-book value of 1.20 and EV to sales ratio of 0.58 continued to highlight its relative undervaluation within the Pharmaceuticals & Biotechnology sector.
Fundamentals that don't lie! This Small Cap from Trading shows consistent growth and price strength over time. A reliable pick you can truly count on.
- - Strong fundamental track record
- - Consistent growth trajectory
- - Reliable price strength
25 June 2026: Week Closes Slightly Lower
The week concluded with Makers Laboratories Ltd closing at Rs.147.30, a modest 0.31% decline from the previous day’s close. Trading volume was subdued at 1,201 shares, reflecting limited market activity. The Sensex also edged down by 0.05% to 36,133.32, indicating a broadly flat market environment. Despite the weekly price decline of 2.42%, the stock’s relative valuation improvements and operational highlights provide a nuanced picture of its current standing.
Holding Makers Laboratories Ltd from ? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Daily Price Comparison: Makers Laboratories Ltd vs Sensex
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-06-22 | Rs.147.80 | -2.09% | 36,342.26 | +0.46% |
| 2026-06-23 | Rs.143.25 | -3.08% | 35,959.97 | -1.05% |
| 2026-06-24 | Rs.145.90 | +1.85% | 36,151.68 | +0.53% |
| 2026-06-25 | Rs.147.30 | +0.96% | 36,133.32 | -0.05% |
Key Takeaways from the Week
Valuation Upgrade Reflects Improved Price Appeal: The upgrade from 'Sell' to 'Hold' by MarketsMOJO was driven by a shift in valuation grade from 'Fair' to 'Attractive'. Makers Laboratories Ltd’s price-to-earnings ratio of 37.11 and EV/EBITDA of 5.51 compare favourably with several peers trading at higher multiples, signalling a more reasonable price point for investors.
Mixed Financial Signals Temper Enthusiasm: Despite recent quarterly highs in net sales (₹35.75 crores) and PBDIT (₹5.27 crores), the company’s longer-term operating profit trend remains negative with a five-year CAGR of -7.99%. Return on equity is modest at 3.22%, indicating limited profitability relative to shareholder funds.
Stock Underperformed Sensex Despite Sector Momentum: The stock declined 2.42% over the week, underperforming the Sensex’s marginal 0.11% fall. This divergence reflects investor caution amid mixed operational results and micro-cap volatility.
Operational Efficiency Evident but Growth Challenges Persist: A return on capital employed of 15.26% suggests efficient capital use, yet the low ROE and negative profit growth highlight ongoing challenges in translating operational gains into shareholder value.
Micro-Cap Status Implies Higher Volatility: Makers Laboratories’ classification as a micro-cap stock entails greater price swings and liquidity considerations, which were evident in the week’s price movements and volume patterns.
Conclusion: A Week of Valuation Optimism Amid Price Pressure
Makers Laboratories Ltd’s week was characterised by a notable upgrade in valuation and investment rating, signalling improved price attractiveness relative to peers. However, the stock’s price declined by 2.42%, underperforming the broader market’s modest correction. The company’s recent operational highlights and valuation metrics offer a cautiously optimistic outlook, but persistent challenges in profitability and growth temper enthusiasm. Investors should consider the micro-cap risks and mixed financial signals when assessing the stock’s prospects going forward.
Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today
